Occam Recruits Ann Taylor to the Board of Unlearn
Unlearn, an 8VC investment, has developed the first machine learning platform for creating Intelligent Control Arms with Digital Twins, allowing drug developers to dramatically improve clinical evidence and trial power, while lowering the risk of trial failure, thereby increasing confidence in clinical trial results.
In late 2020, Occam recruited Ann Taylor, MD to the Board of Unlearn. Ann brings with her deep experience in clinical development, having served as CMO for AstraZeneca until 2021.
Recent Placements
Occam Global is a trusted executive search, consulting, and investment partner for leaders and investors shaping the future of life sciences, deep tech, and venture capital. Since 2012, we’ve helped build high-performing teams and advised visionary companies from stealth to public markets. Our success stems from exceptional access to rare talent, deep sector expertise, and a commitment to results guided by elevated ethics and enlightened aggression.